Dernières nouvelles pour Enveric Biosciences (NASDAQ:ENVB) Stock

Enveric Biosciences

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Enveric Biosciences Inc

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy and maintains $36 price target.

News

Price Target

Analyst Ratings

OMER

D. Boral Capital Maintains Buy on Omeros, Maintains $36 Price Target

Biotech

General

ITOS

iTeos Has Initiated A Targeted Review Of Strategic Alternatives To Maximize Shareholder Value

–&nbsp;GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival
–&nbsp;Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program
–&nbsp;iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value
WATERTOWN, Mass. and GOSSELIES, Belgium, May 13, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported topline results from an updated interim analysis of GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos' development partner GSK assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer (NSCLC).
The GALAXIES Lung-201 data continued to demonstrate clinically meaningful improvements in the trial's primary endpoint of objective response rate (ORR), however the analysis did not meet established criteria for clinically meaningful improvements in the secondary endpoint of progression free survival in the belrestotug + dostarlimab combination cohorts versus dostarlimab monotherapy. Additionally, an interim analysis of the GALAXIES H&amp;N-202 Phase 2 trial showed a trend below the meaningful threshold for ORR in the belrestotug combination cohorts vs. dostarlimab monotherapy in PD-L1 positive head and neck squamous cell carcinoma.
Based on these results, iTeos and GSK have made the decision to terminate the belrestotug development program and end the collaboration. All belrestotug-containing cohorts are ending, and any new enrollment in the ongoing GALAXIES Lung-301 Phase 3 trial is ending. GSK is communicating with investigators, institutional review boards, ethics committees, and health authorities about next steps for appropriate management of currently enrolled patients. The Company is taking immediate steps to preserve capital and has initiated a targeted process to identify opportunities that preserve and maximize shareholder value. iTeos has engaged TD Cowen to advise on this process.&nbsp;

iTeos Reports Topline Interim Results From GALAXIES Lung-201 Study Of Belrestotug + Dostarlimab In First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients; Did Not Meet Established Criteria For Clinically Meaningful Improvements In Progression Free Survival; Based On Totality Of Data, ITeos And GSK Have Agreed To Terminate The Belrestotug Development Program

WIIM

MVIS

MicroVision shares are trading lower after the company reported worse-than-expected Q1 financial results.

NRGV

NRGV stock has given up its prior loss. Energy Vault Holdings shares were trading lower after the company reported worse-than-expected Q1 financial results.

Anthony Scaramucci believes Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is in the midst of a structural transformation, from a volatile tech-aligned investment to a maturing global asset more comparable <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44932297/digital-gold-or-fools-gold-the-real-value-behind-bitcoin-in-2025#:~:text=In%20truth%2C%20Bitcoin%20isn't,stored%20with%20zero%20physical%20footprint.">to digital gold</a>.
What Happened: In an <a href="https://x.com/Cointelegraph/status/1922185336572010570">interview</a> with Bloomberg on Monday, the SkyBridge Capital founder said Bitcoin's growing adoption and long-term holding behavior are driving this evolution, dampening volatility and pushing it into the asset class category rather than a speculative investment.
"Ultimately, what we see is the evolution of Bitcoin from being sort of a tech asset tied to the Mag 7 or Nasdaq to something that's more akin to digital gold," Scaramucci said. 
As wallet growth accelerates, now estimated at over 300 million globally, he anticipates that broader adoption could lead to a billion holders, a milestone that would reduce price swings and reinforce Bitcoin's role in long-term portfolios.
He added that this cycle of increasing wallet distribution, institutional participation and reduced volatility could form a positive feedback loop, encouraging more large holders to enter the market.
The shift, he argued, prompts a key distinction: "Is Bitcoin an investment, or is it an asset class?" 
If the latter, he said, then valuations would shift from a market cap in the trillions, similar to tech stocks, to the levels of gold, which commands over $22 trillion in global value.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45352237/nakamoto-holdings-raises-710m-merges-with-kindlymd-to-build-bitcoin-treasury-holding-company">Nakamoto Holdings Raises $710M, Merges With KindlyMD To Build Bitcoin Treasury Holding Company</a>
Why It Matters: The remarks come as Bitcoin continues to consolidate above the $103,000 mark.
Bitfinex analysts report steady spot volume and neutral funding, with no immediate macro threats. 
Support lies near $98,500, while resistance stands between $104,000 and $106,000. 
In a note sent to Benzinga, the analysts caution that while momentum remains intact, Bitcoin may enter a consolidation phase, potentially delaying any new all-time highs until June as supply and demand stabilize above key psychological thresholds.
Medium-term conditions remain constructive. 
Bitcoin has outperformed equities and altcoins, and ETF inflows continue to show consistency. 
Barring any shocks from CPI data or central bank guidance, analysts see further upside in the months ahead.
Long-term, Bitfinex analysts echo Scaramucci's perspective, stating that Bitcoin is increasingly behaving like a macro reserve asset. 
Structural supply limitations, global ETF adoption, and a shift in U.S. regulatory tone have strengthened Bitcoin's fundamental outlook. 
Price targets between $150,000 and $180,000 for the current cycle remain in play, contingent on broader market stability.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45349057/strategy-buys-134b-in-bitcoin-at-99856-cites-155-btc-yield">Strategy Buys $1.34B In Bitcoin At $99,856, Cites 15.5% BTC Yield</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Anthony Scaramucci Says Bitcoin Is Evolving From A Tech Asset To Digital Gold

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Holdings shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Needham analyst Joshua Reilly reiterates Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) with a Buy and maintains $750 price target.

Reiteration

Needham Reiterates Buy on Tyler Technologies, Maintains $750 Price Target

RLGT

Radiant Logistics shares are trading higher after the company reported better-than-expected Q3 financial results.

SNGX

Soligenix shares are trading lower after the company reported worse-than-expected Q1 EPS results.

D. Boral Capital analyst Jesse Sobelson maintains US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) with a Buy and maintains $3.5 price target.

USEG

D. Boral Capital Maintains Buy on US Energy, Maintains $3.5 Price Target

CHRS

Coherus BioSciences shares are trading lower. The company reported Q1 financial results.

VTSI

VirTra shares are trading higher after the company reported better-than-expected Q1 financial results.

Landstar also announced today that its Board of Directors declared a quarterly dividend of $0.40 per share payable on June 24, 2025, to stockholders of record as of the close of business on June 5, 2025. This quarterly dividend includes a $0.04 per share increase, or 11% over the amount of the Company's regular quarterly dividend declared following each of the prior three quarters.

Dividends

LSTR

Landstar System Boosts Quarterly Dividend By 11% To $0.40/Share

Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) affirms FY2025 sales outlook from $410.00 million-$425.00 million to $410.00 million-$425.00 million vs $410.79 million estimate.

Guidance

NYAX

Nayax Affirms FY2025 Sales Guidance of $410.00M-$425.00M vs $410.79M Est

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Piper Sandler raised ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) price target from $9 to $11. Piper Sandler analyst Brent Bracelin maintained a Neutral rating. ZoomInfo shares closed at $10.31 on Monday. <a href="https://www.benzinga.com/quote/ZI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut the price target for Annexon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) from $16 to $11. Needham analyst Joseph Stringer maintained a Buy rating. Annexon shares closed at $1.77 on Monday. <a href="https://www.benzinga.com/quote/ANNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point slashed NexPoint Residential Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) price target from $50 to $42.5. Compass Point analyst Merrill Ross downgraded the stock from Buy to Neutral. NexPoint Residential Trust shares closed at $37.53 on Monday. <a href="https://www.benzinga.com/quote/NXRT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson lowered the price target for Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from $29 to $21. DA Davidson analyst Rudy Kessinger downgraded the stock from Neutral to Underperform. Rapid7 shares closed at $26.74 on Monday. <a href="https://www.benzinga.com/quote/RPD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark slashed the price target for indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) from $8 to $6. Benchmark analyst Cody Acree maintained a Buy rating. indie Semiconductor shares closed at $2.64 on Monday. <a href="https://www.benzinga.com/quote/INDI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) price target from $5 to $0.39. Leerink Partners analyst Daina Graybosch downgraded the stock from Outperform to Market Perform. Affimed shares settled at $0.6930 on Monday. <a href="https://www.benzinga.com/quote/AFMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays increased Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) price target from $69 to $90. Barclays analyst Julian Mitchell upgraded the stock from Equal-Weight to Overweight. Stanley Black &amp; Decker shares closed at $72.53 on Monday. <a href="https://www.benzinga.com/quote/SWK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut BILL Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) price target from $105 to $75. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. BILL Holdings shares closed at $47.37 on Monday.  <a href="https://www.benzinga.com/quote/BILL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies increased the price target for Matson, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATX#NYSE">MATX</a>) from $125 to $135. Jefferies analyst Omar Nokta maintained a Buy rating. Matson shares settled at $113.94 on Monday. <a href="https://www.benzinga.com/quote/MATX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. slashed Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) price target from $50 to $45. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Neurogene shares closed at $17.70 on Monday. <a href="https://www.benzinga.com/quote/NGNE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SWK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-1024x586.png" alt="" class="wp-image-913331" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

AFMD

ANNX

BILL

INDI

MATX

NGNE

NXRT

Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

D. Boral Capital analyst Jesse Sobelson maintains Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) with a Buy and lowers the price target from $3 to $2.5.

D. Boral Capital Maintains Buy on Microvision, Lowers Price Target to $2.5

ADAP

Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) with a Buy and maintains $4.25 price target.

Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target

Earnings

Earnings Beats

Earnings Misses

Landstar System Q1 EPS $0.85 Misses $0.99 Estimate, Sales $1.15B Beat $1.13B Estimate

Press Releases

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Enveric Biosciences Announces Closing of $5 Million Public Offering

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Small-Caps Under $2 on the Move: ENVB, ONVO, TRNR, PRSO, PNPN.V Gaining Momentum

Enveric Biosciences CEO Issues Letter to Shareholders

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

ENVB

ONVO

PNPNF

PRSO

TRNR

TSXV:PNPN

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Artelo Biosciences

Biofrontera

CNS Pharma

Evoke Pharma

Eyenovia

Jaguar Health

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

cbdMD

HC Wainwright & Co.

Alliance Global Partners

Doctor,Hand,Holding,A,Holographic,Of,Human,Brain,In,Healthcare

Enveric Biosciences Presents Compelling Preclinical Data On Lead Compound EB-003 At 7th Neuropsychiatric Drug Summit

Comments

Enveric Biosciences

Actualités

Dernières nouvelles pour Enveric Biosciences (NASDAQ:ENVB) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL